These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18071309)

  • 1. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor.
    Tao WJ; Lin H; Sun T; Samanta AK; Arlinghaus R
    Oncogene; 2008 May; 27(22):3194-200. PubMed ID: 18071309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.
    Tokunaga M; Ezoe S; Tanaka H; Satoh Y; Fukushima K; Matsui K; Shibata M; Tanimura A; Oritani K; Matsumura I; Kanakura Y
    J Biol Chem; 2010 Oct; 285(41):31774-82. PubMed ID: 20663870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
    Carlesso N; Frank DA; Griffin JD
    J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
    Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
    Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Jak2 is involved in c-Myc induction by Bcr-Abl.
    Xie S; Lin H; Sun T; Arlinghaus RB
    Oncogene; 2002 Oct; 21(47):7137-46. PubMed ID: 12370803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
    Hantschel O; Warsch W; Eckelhart E; Kaupe I; Grebien F; Wagner KU; Superti-Furga G; Sexl V
    Nat Chem Biol; 2012 Jan; 8(3):285-93. PubMed ID: 22286129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
    Spiekermann K; Pau M; Schwab R; Schmieja K; Franzrahe S; Hiddemann W
    Exp Hematol; 2002 Mar; 30(3):262-71. PubMed ID: 11882364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
    Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
    Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.
    Samanta A; Perazzona B; Chakraborty S; Sun X; Modi H; Bhatia R; Priebe W; Arlinghaus R
    Leukemia; 2011 Mar; 25(3):463-72. PubMed ID: 21183952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL affects STAT5A and STAT5B differentially.
    Schaller-Schönitz M; Barzan D; Williamson AJ; Griffiths JR; Dallmann I; Battmer K; Ganser A; Whetton AD; Scherr M; Eder M
    PLoS One; 2014; 9(5):e97243. PubMed ID: 24836440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition.
    Donato NJ; Wu JY; Zhang L; Kantarjian H; Talpaz M
    Blood; 2001 May; 97(9):2846-53. PubMed ID: 11313280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines.
    Liu RY; Fan C; Garcia R; Jove R; Zuckerman KS
    Blood; 1999 Apr; 93(7):2369-79. PubMed ID: 10090948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
    Nieborowska-Skorska M; Slupianek A; Skorski T
    Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.
    Nishihara T; Miura Y; Tohyama Y; Mizutani C; Hishita T; Ichiyama S; Uchiyama T; Tohyama K
    Int J Hematol; 2003 Oct; 78(3):233-40. PubMed ID: 14604282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoiesis in the absence of janus-kinase 2: BCR-ABL induces red cell formation in JAK2(-/-) hematopoietic progenitors.
    Ghaffari S; Kitidis C; Fleming MD; Neubauer H; Pfeffer K; Lodish HF
    Blood; 2001 Nov; 98(10):2948-57. PubMed ID: 11698276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway.
    Tauchi T; Yoshimura A; Ohyashiki K
    Exp Hematol; 2001 Mar; 29(3):356-61. PubMed ID: 11274764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARG tyrosine kinase activity is inhibited by STI571.
    Okuda K; Weisberg E; Gilliland DG; Griffin JD
    Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
    Chai SK; Nichols GL; Rothman P
    J Immunol; 1997 Nov; 159(10):4720-8. PubMed ID: 9366395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P210 Bcr-Abl interacts with the interleukin-3 beta c subunit and constitutively activates Jak2.
    Wilson-Rawls J; Liu J; Laneuville P; Arlinghaus RB
    Leukemia; 1997 Apr; 11 Suppl 3():428-31. PubMed ID: 9209414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.